<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">724</article-id><article-id pub-id-type="doi">10.25692/ACEN.2021.1.5</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The diagnostic significance of neurofilament heavy chains in cerebrospinal fluid in amyotrophic lateral sclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Исследование диагностической значимости тяжелых цепей нейрофиламентов в цереброспинальной жидкости при боковом амиотрофическом склерозе</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vladykina</surname><given-names>Anastasia V.</given-names></name><name xml:lang="ru"><surname>Владыкина</surname><given-names>Анастасия Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nazarov</surname><given-names>Vladimir D.</given-names></name><name xml:lang="ru"><surname>Назаров</surname><given-names>Владимир Дмитриевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Krasnov</surname><given-names>Vladimir S.</given-names></name><name xml:lang="ru"><surname>Краснов</surname><given-names>Владимир Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Koroleva</surname><given-names>Ekaterina I.</given-names></name><name xml:lang="ru"><surname>Королева</surname><given-names>Екатерина Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fedorova</surname><given-names>Polina A.</given-names></name><name xml:lang="ru"><surname>Федорова</surname><given-names>Полина Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Moshnikova</surname><given-names>Anna N.</given-names></name><name xml:lang="ru"><surname>Мошникова</surname><given-names>Анна Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mazing</surname><given-names>Aleksandra V.</given-names></name><name xml:lang="ru"><surname>Мазинг</surname><given-names>Александра Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lapin</surname><given-names>Sergey V.</given-names></name><name xml:lang="ru"><surname>Лапин</surname><given-names>Сергей Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Emanuel</surname><given-names>Vladimir L.</given-names></name><name xml:lang="ru"><surname>Эмануэль</surname><given-names>Владимир Леонидович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rudenko</surname><given-names>Dmitriy I.</given-names></name><name xml:lang="ru"><surname>Руденко</surname><given-names>Дмитрий Игоревич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stuchevskaya</surname><given-names>Fatima R.</given-names></name><name xml:lang="ru"><surname>Стучевская</surname><given-names>Фатима Рамазановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zatakovenko</surname><given-names>Sergey M.</given-names></name><name xml:lang="ru"><surname>Затаковенко</surname><given-names>Сергей Михайлович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pavlova</surname><given-names>Tatyana A.</given-names></name><name xml:lang="ru"><surname>Павлова</surname><given-names>Татьяна Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alekseeva</surname><given-names>Tatyana M.</given-names></name><name xml:lang="ru"><surname>Алексеева</surname><given-names>Татьяна Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Goldobin</surname><given-names>Vitaliy V.</given-names></name><name xml:lang="ru"><surname>Голдобин</surname><given-names>Виталий Витальевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>vladykina.anastasiya@gmail.com</email><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pavlov First St. Petersburg State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет&#13;
имени академика И.П. Павлова»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">City Multidisciplinary Hospital № 2</institution></aff><aff><institution xml:lang="ru">СПб ГБУЗ «Городская многопрофильная больница № 2»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Almazov National Medical Research Centre</institution></aff><aff><institution xml:lang="ru">ФГБУ «НМИЦ имени В.А. Алмазова»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">North-Western State Medical University named after I.I. Mechnikov</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-03-24" publication-format="electronic"><day>24</day><month>03</month><year>2021</year></pub-date><volume>15</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>43</fpage><lpage>50</lpage><history><date date-type="received" iso-8601-date="2021-03-24"><day>24</day><month>03</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Vladykina A.V., Nazarov V.D., Krasnov V.S., Koroleva E.I., Fedorova P.A., Moshnikova A.N., Mazing A.V., Lapin S.V., Emanuel V.L., Rudenko D.I., Stuchevskaya F.R., Zatakovenko S.M., Pavlova T.A., Alekseeva T.M., Goldobin V.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Vladykina A.V., Nazarov V.D., Krasnov V.S., Koroleva E.I., Fedorova P.A., Moshnikova A.N., Mazing A.V., Lapin S.V., Emanuel V.L., Rudenko D.I., Stuchevskaya F.R., Zatakovenko S.M., Pavlova T.A., Alekseeva T.M., Goldobin V.V.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Vladykina A.V., Nazarov V.D., Krasnov V.S., Koroleva E.I., Fedorova P.A., Moshnikova A.N., Mazing A.V., Lapin S.V., Emanuel V.L., Rudenko D.I., Stuchevskaya F.R., Zatakovenko S.M., Pavlova T.A., Alekseeva T.M., Goldobin V.V.</copyright-holder><copyright-holder xml:lang="ru">Vladykina A.V., Nazarov V.D., Krasnov V.S., Koroleva E.I., Fedorova P.A., Moshnikova A.N., Mazing A.V., Lapin S.V., Emanuel V.L., Rudenko D.I., Stuchevskaya F.R., Zatakovenko S.M., Pavlova T.A., Alekseeva T.M., Goldobin V.V.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/724">https://annaly-nevrologii.com/pathID/article/view/724</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Early diagnosis of amyotrophic lateral sclerosis (ALS) is difficult because of the low sensitivity of clinical criteria at the early stages of the disease and the lack of reliable laboratory biomarkers. Neuron destruction leads to the release of excessively accumulated phosphorylated neurofilament heavy chains (pNFH) in the cerebrospinal fluid (CSF) and may potentially be used for early diagnosis of ALS. In addition, pNFH may have predictive significance.</p> <p><bold>Aim.</bold> To investigate the clinical significance of elevated neurofilament heavy chain levels in the CSF in ALS.</p> <p><bold>Materials and methods.</bold> The study included 33 patients with ALS diagnosed using the El Escorial criteria, 30 patients in the control group (post phlebectomy), as well as 28 patients in the comparison group: 16 patients with multiple sclerosis, 5 with autoimmune encephalitis, 1 with tick-borne encephalitis, 2 with primary lateral sclerosis, 1 with progressive muscle atrophy and 3 with other conditions (restless leg syndrome, compressive myelopathy and paraneoplastic cerebellar degeneration). All patients underwent a lumbar puncture, with pNFH levels measured using ELISA.</p> <p><bold>Results. </bold>A statistically significant difference in pNFH concentration was found between ALS patients and patients in the comparison group (<italic>p</italic> &lt; 0.0001). At a threshold pNFH level, which was taken to be 0.785 ng/ml, the test sensitivity and specificity were 94% and 86%, respectively. Elevated pNFH levels in the CSF of patients with confirmed ALS were found in 94% of cases, compared with only 14% of patients in the comparison group. A statistically significant difference in pNFH concentration was found between the group with ALS and the control group (<italic>p</italic> &lt; 0.0001). A negative correlation was found between pNFH level in the CSF and disease duration (<italic>r</italic> = –0.5172; <italic>p </italic>= 0.0029). A positive correlation was also found between the speed of disease progression and pNFH concentration (<italic>r</italic> = 0.5480; <italic>p </italic>= 0.001).</p> <p><bold>Conclusion.</bold> The results of this study demonstrate the high clinical significance of pNFH in the CSF in ALS.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Ранняя постановка диагноза бокового амиотрофического склероза (БАС) затруднена из-за низкой чувствительности клинических критериев на начальных этапах развития болезни, а также отсутствия достоверных лабораторных биомаркеров. При разрушении нейрона накопленные в избытке гиперфосфорилированные тяжёлые цепи нейрофиламентов (ТНФ) высвобождаются и попадают в цереброспинальную жидкость (ЦСЖ), что потенциально может использоваться при ранней диагностике БАС. Кроме этого, ТНФ могут обладать прогностической значимостью.</p> <p><bold>Цель </bold>работы — исследование клинической значимости повышения концентрации ТНФ в ЦСЖ при БАС.</p> <p><bold>Материалы и методы.</bold> Исследование включало 33 пациентов с диагностированным по критериям El Escorial БАС, 30 пациентов группы контроля (после флебэктомии), а также 28 пациентов группы сравнения: с рассеянным склерозом (<italic>n</italic> = 16), аутоиммунным энцефалитом (<italic>n</italic> = 5), клещевым энцефалитом (<italic>n</italic> = 1), первичным латеральным склерозом (<italic>n</italic> = 2), прогрессирующей мышечной атрофией (<italic>n</italic> = 1), другими патологиями (синдром беспокойных ног, компрессионная миелопатия, паранеопластическая дегенерация мозжечка; <italic>n</italic> = 3). У всех пациентов была проведена люмбальная пункция, после чего содержание ТНФ определяли с помощью иммуноферментного анализа.</p> <p><bold>Результаты. </bold>Выявлена статистически значимая разница концентрации ТНФ у пациентов с БАС и у пациентов из группы сравнения (<italic>p</italic> &lt; 0,0001). При пороговой концентрации ТНФ (0,785 нг/мл) чувствительность и специфичность теста составили 94 и 86% соответственно. Повышенная концентрация ТНФ в ЦСЖ у пациентов с подтверждённым БАС наблюдалась в 94% случаев, в группе сравнения — лишь у 14% пациентов. Между группой БАС и группой контроля выявлена статистически значимая разница в концентрации ТНФ (<italic>p</italic> &lt; 0,0001). Обнаружены отрицательная корреляция между концентрацией ТНФ в ЦСЖ и длительностью течения заболевания (<italic>r</italic> = –0,5172; <italic>p </italic>= 0,0029), положительная корреляция между скоростью прогрессии заболевания и концентрацией ТНФ (<italic>r</italic> = 0,5480; <italic>p </italic>= 0,001).</p> <p><bold>Выводы.</bold> Результаты проведённого исследования свидетельствуют о высокой клинической значимости ТНФ в ЦСЖ при БАС.</p></trans-abstract><kwd-group xml:lang="en"><kwd>amyotrophic lateral sclerosis</kwd><kwd>neurofilaments</kwd><kwd>neurofilament heavy chains</kwd><kwd>biomarkers</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>боковой амиотрофический склероз</kwd><kwd>нейрофиламенты</kwd><kwd>тяжёлые цепи нейрофиламентов</kwd><kwd>биомаркеры</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Zavalishin I.A. (ed.) [Amyotrophic lateral sclerosis]. Moscow, 2009. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Завалишин И.А. (ред.) Боковой амиотрофический склероз. М.: ГЭОТАР-Медиа, 2009.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Gusev E.I., Konovalov A.N. (eds.) [Clinical Practice Guidelines. Neurology and Neurosurgery]. 2nd ed. Moscow, 2015. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Гусев Е.И., Коновалов А.Н. (ред.) Клинические рекомендации. Неврология и нейрохирургия. 2-е изд. М.: ГЭОТАР-Медиа, 2015.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Geevasinga N., Menon P., Scherman D.B. et al. Diagnostic criteria in amyotrophic lateral sclerosis: A multicenter prospective study. Neurology. 2016; 87(7): 684–690. DOI: 10.1212/WNL.0000000000002988. PMID: 27440148.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Brown R.H. Jr. Amyotrophic lateral sclerosis and other motor neuron diseases. In: Hauser S.L. (ed.) Harrison’s neurology in clinical medicine. 4th ed. N.Y.: McGraw-Hill Education, 2017: 449–459.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>De Vos K.J., Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol Dis. 2017; 105: 283–299. DOI: 10.1016/J.NBD.2017.02.004. PMID: 28235672.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Petzold A. Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005; 233: 183–198. DOI: 10.1016/J.JNS.2005.03.015. PMID: 15896809.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Nixon R.A., Lewis S.E. Differential turnover of phosphate groups on neurofilament subunits in mammalian neurons in vivo. J. Biol. Chem. 1986; 261(35): 16298–16301. PMID: 3782120.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Gong C., Shaikh S., Wang J., et al. Phosphatase activity toward abnormally phosphorylated τ: decrease in Alzheimer disease brain. J Neurochem. 1995; 65: 732–738. DOI: 10.1046/J.1471-4159.1995.65020732.x.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Yuan A., Rao M.V., Veeranna, Nixon R.A. Nixon neurofilaments at a glance. J Cell Sci. 2012; 125: 3257–3263. DOI: 10.1242/JCS.104729. PMID: 22956720.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Williamson T.L., Bruijn L.I., Zhu Q., et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA. 1998; 95(16): 9631–9636. DOI: 10.1073/PNAS.95.16.9631. PMID: 9689132.</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Vorob'eva A.A., Fominykh V.V., Onufriev M.V. et al. [The usage of phosphorylated NfH as a neurodegeneration marker in demyelinating diseases of CNS]. Neyrokhimiya [Neurochemistry]. 2014; 31(3): 254–259. DOI: 10.7868 / S1027813314030145. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Воробьева А.А., Фоминых В.В., Онуфриев М.В. и др. Использование тяжелых цепей фосфорилированных нейрофиламентов в качестве маркера нейродегенерации при демиелизирующих заболеваниях ЦНС. Нейрохимия. 2014; 31(3): 254–259. DOI: 10.7868/S1027813314030145.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Brylev L.V. [The role of cell cycle proteins and proteolytic enzymes in the pathogenesis of amyotrophic lateral sclerosis: Thesis Cand. Sci. (Med.)]. Moscow, 2009. 143 p. (in Russ.)</mixed-citation><mixed-citation xml:lang="ru">Брылев Л.В. Роль белков клеточного цикла и протеолитических ферментов в патогенезе бокового амиотрофического склероза: дис. … канд. мед. наук. М., 2009. 143 с.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Poesen K., De Schaepdryver M., Stubendorff B., et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017; 88(24): 2302–2309. DOI: 10.1212/WNL.0000000000004029. PMID: 28500227.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Reijn T.S., Abdo W.F., Schelhaas H.J., et al. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009; 256(4): 615–619. DOI: 10.1007/s00415-009-0131-z. PMID: 19296046.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Xu Z., Henderson R.D., David M., et al. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS One. 2016; 11(10): e0164625. DOI: 10.1371/journal.pone.0164625. PMID: 27732645.</mixed-citation></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Polonsky Е.L., Skulyabin D.I., Lapin S.V. et al. [Polymorphism of autoimmune encephalitis]. Annals of clinical and experimental neurology. 2019; 13(2): 79– 91. DOI: 10.25692/ACEN.2019.2.9. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Полонский Е.Л., Скулябин Д.И., Лапин С.В. и др. Полиморфизм аутоиммунного энцефалита. Анналы клинической и экспериментальной неврологии. 2019; 13(2): 79–91. DOI: 10.25692/ACEN.2019.2.9.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>Li J., Gu Y., An H., et al. Cerebrospinal fluid light and heavy neurofilament level increased in anti‐N‐methyl‐D‐aspartate receptor encephalitis. Brain Behav. 2019; 9:e01354. DOI: 10.1002/brb3.1354.</mixed-citation></ref></ref-list></back></article>
